Preventing food allergy in infancy and childhood: Systematic review of randomised controlled trials

Debra de Silva1, Susanne Halken2, Chris Singh1

  • 1The Evidence Centre Ltd, London, UK.

Insights

Preventing infant food allergies may involve early introduction of certain foods like egg and peanut. However, evidence for many other interventions, including dietary changes and supplements, is uncertain.

Area of Science:

  • Allergy and Immunology
  • Pediatric Nutrition
  • Preventive Medicine

Background:

  • Immediate-onset/IgE-mediated food allergy prevention strategies are crucial for public health.
  • Guidelines by the European Academy of Allergy and Immunology (EAACI) require updated evidence.
  • Understanding effective interventions is key to reducing the burden of food allergies.

Purpose of the Study:

  • To systematically review interventions for preventing immediate-onset/IgE-mediated food allergy.
  • To inform the development of new European Academy of Allergy and Immunology (EAACI) guidelines.
  • To synthesize current evidence on the efficacy of various preventive strategies.

Main Methods:

  • Systematic review utilizing the GRADE approach.
  • Comprehensive search of eleven databases from 1946 to October 2019.
  • Narrative synthesis of findings due to study heterogeneity in interventions, populations, and outcomes.

Main Results:

  • Early introduction of well-cooked egg (4-6 months) likely reduces hen's egg allergy risk.
  • Introducing peanut from 4-11 months probably significantly reduces peanut allergy risk in high-prevalence countries.
  • Evidence for many interventions (dietary avoidance, supplements, probiotics, breastfeeding, hydrolyzed formulas) is very uncertain or suggests little to no effect.

Conclusions:

  • Early introduction of specific allergens like egg and peanut shows promise in preventing allergies.
  • Significant knowledge gaps remain in food allergy prevention, particularly regarding early allergen introduction.
  • Further research is needed to validate findings in diverse populations and refine prevention guidelines.
Abstract

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Allergic Reactions02:06

Allergic Reactions

Overview
31.7K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
172
Allergic Drug Reactions01:27

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
664
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
169